RxDoctor Payments Data

Abdulmassih Abdulmassih, MD

Family Medicine · Chicago, ILNPI 1629045778

Payments from drug & device makers

$23,602in general payments, 2019–2025

Across 1,370 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$830
  • plus $12K from 54 others

What the payments were for

  • Food & beverage$23,31799%
  • Education$2261%
  • Gifts$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)233$3,123
AstraZeneca(2 entities)135$2,472
Novo Nordisk103$1,924
Pfizer91$1,489
Lilly USA, LLC86$1,465
Boehringer Ingelheim49$830
Mylan Specialty L.p.31$823
Merck54$738
Mannkind Corporation33$687
GSK35$661
Amarin Pharma, Inc.36$656
Bayer33$631
Amgen(2 entities)34$618
Novartis29$603
Johnson & Johnson40$591
Otsuka America Pharmaceutical, Inc.33$552
E.r. Squibb & Sons, L.L.C.14$325
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC20$316
Sunovion Pharmaceuticals Inc.17$305
Almatica Pharma LLC17$291
Dexcom, Inc.9$279
Astellas Pharma US Inc10$266
Lundbeck LLC25$264
Corium, LLC10$208
Seqirus USA Inc8$180
Scilex Pharmaceuticals Inc.10$177
Exact Sciences8$176
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)9$163
Takeda Pharmaceuticals U.S.A., Inc.10$163
Optinose US, Inc.9$161
Redhill Biopharma Inc.8$160
Teva Pharmaceuticals USA, Inc.6$149
Sanofi-aventis U.S. LLC8$146
Genentech USA, Inc.7$139
Insulet Corporation6$124
Abbott6$119
IBSA Pharma Inc.6$114
Biohaven Pharmaceutical Holding Company Ltd.7$112
Kowa Pharmaceuticals America, Inc.7$103
Ironwood Pharmaceuticals, Inc6$94
Xeris Pharmaceuticals, Inc.5$92
Esperion Therapeutics, Inc.6$88
Sanofi Pasteur Inc.4$84
Supernus Pharmaceuticals, Inc.5$80
Hikma Pharmaceuticals USA5$73
Phathom Pharmaceuticals, Inc.6$69
Biohaven Pharmaceuticals, Inc.5$69
Phadia US Inc.4$68
Ardelyx, Inc.3$65
Sumitomo Pharma America, Inc.3$60
Corcept Therapeutics2$53
Verona Pharma, Inc.2$53
Daiichi Sankyo Inc.3$45
Melinta Therapeutics, LLC3$38
Baxter Healthcare1$36
Avanir Pharmaceuticals, Inc.2$35
Hologic Sales And Service, LLC2$35
Shield Therapeutics Inc2$34
Eyevance Pharmaceuticals LLC2$25
Inspire Medical Systems, Inc.1$25

How this compares

$23,602 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$717,415
Medicare patients
776
Services billed
15,559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate269$211,128
EliquisApixaban403$193,395
FarxigaDapagliflozin Propanediol239$173,089
OzempicSemaglutide163$170,786
Diclofenac Sodium602$139,409
JardianceEmpagliflozin169$130,274
DapagliflozinDapagliflozin Propanediol177$88,960
LinzessLinaclotide128$85,873
MounjaroTirzepatide71$84,741
TrulicityDulaglutide85$79,274
XifaxanRifaximin22$72,692
NuplazidPimavanserin Tartrate22$55,639
RybelsusSemaglutide39$53,909
TradjentaLinagliptin80$45,256
GlyxambiEmpagliflozin/Linagliptin56$43,144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr, Janumet$738$244,337315 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Combivent Respimat$830$233,516338 claims
Novo NordiskOzempic, Rybelsus$1,924$224,694202 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$2,472$208,670303 claims
PfizerEliquis, Abrysvo$1,489$208,372449 claims
Lilly USA, LLCMounjaro, Trulicity$1,465$164,015156 claims
AbbVieLinzess, Namzaric$3,123$103,910161 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$316$72,69222 claims
GSKShingrix, Trelegy Ellipta$661$53,412186 claims
NovartisEntresto$603$36,69448 claims
AmgenProlia$618$25,83415 claims
Astellas Pharma US IncMyrbetriq$266$23,17542 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →